Episode

E130: Telitacicept for SLE

Podcast: The Evidence Based Rheumatology Podcast
Published: Dec 22, 2025
Duration seconds: 786
Processing state: not_requested
Canonical source: https://msputman.podbean.com/e/e130-telitacicept-for-sle/
Audio: https://mcdn.podbean.com/mf/web/vgu8xxnmt9ztaztd/e130.mp3
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e130-telitacicept-for-sle
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e130-telitacicept-for-sle/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719